Premenstrual Syndrome (PMS) (cont.)
Other Works Consulted
Abajo FJ, Garcia-Rodriguez LA (2008). Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Archives of General Psychiatry, 65(7): 795–803.
Berga SL, Spencer JB (2009). Premenstrual syndrome. In EG Nabel, ed., ACP Medicine, section 16, chap. 3. New York: WebMD.
Davis AJ, Johnson SR (2000, reaffirmed 2010). Premenstrual syndrome. ACOG Practice Bulletin No. 15, pp. 1–9. Washington, DC: American College of Obstetricians and Gynecologists.
Kwan I, Onwude JL (2009). Premenstrual syndrome, search date July 2009. Online version of BMJ Clinical Evidence: http://www.clinicalevidence.com.
Reid RL (2008). Premenstrual syndrome. In RS Gibbs et al., eds., Danforth's Obstetrics and Gynecology, 10th ed., pp. 672–681. Philadelphia: Lippincott Williams and Wilkins.
Twogood S, Israel J (2010). Premenstrual syndrome. In Management of Common Problems in Obstetrics and Gynecology, 5th ed., pp. 267–270. Chichester, UK: Wiley-Blackwell.
U.S. Food and Drug Administration (2005). FDA Public Health Advisory: Paroxetine. Available online: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051731.htm.
Yonkers KA, et al. (2005). Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics and Gynecology, 106(3): 492–501.
eMedicineHealth Medical Reference from Healthwise
To learn more visit Healthwise.org
© 1995-2014 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.